Article Information
History
- July 30, 2020.
Article Versions
- Version 1 (June 9, 2020 - 10:35).
- You are currently viewing Version 2 of this article (July 30, 2020 - 14:30).
- Version 3 (October 1, 2020 - 12:42).
- Version 4 (April 6, 2021 - 15:06).
- Version 5 (April 7, 2021 - 08:54).
- View Version 6, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Herzog Sereina, PhD1,*,+,
- De Bie Jessie, PhD2,3,*,
- Prof Abrams Steven3,4,
- Wouters Ine, PhD2,
- Ekinci Esra, MSc2,
- Patteet Lisbeth, PhD5,
- Coppens Astrid, MSc5,
- De Spiegeleer Sandy, MSc6,
- Prof Beutels Philippe1,
- Prof Van Damme Pierre2,
- Prof Hens Niel1,4 and
- Prof Theeten Heidi2
- 1Centre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, B-2610 Wilrijk, Belgium
- 2Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, B-2610 Wilrijk, Belgium
- 3Global Health Institute, Department of Epidemiology and Social Medicine, University of Antwerp, B-2610 Wilrijk, Belgium
- 4Data Science Institute, I-BioStat, UHasselt, B-3500 Hasselt, Belgium
- 5Algemeen Medisch Laboratorium (AML), Sonic Healthcare, B-2020 Antwerp, Belgium
- 6Laboratoire Luc OLIVIER, B-5380 Fernelmont, Belgium
- ↵+Corresponding author: Sereina Herzog, Centre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Universiteitsplein, 1 B-2610 Wilrijk, Belgium; herzog.sereina{at}gmail.com
↵* Herzog Sereina and De Bie Jessie contributed equally to this paper
Posted July 30, 2020.
Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium – a prospective cross-sectional nationwide study of residual samples
